Skip to main content
Premium Trial:

Request an Annual Quote

Oncore Pharma Signs European Marketing Deal for Colorectal Cancer Test

NEW YORK — Oncore Pharma said today that it has partnered with Dutch medical testing firm BodyCheck to commercialize the ColonSentry colorectal cancer test in Belgium, the Netherlands, and Luxembourg in a deal valued at $61.8 million. 

ColonSentry is a blood-based test designed to evaluate the expression of seven genes in order to determine an individual's current risk for colorectal cancer relative to an average risk population. Cambridge, Massachusetts-based Oncore acquired the rights to commercialize the test in all countries outside the US and Canada from StageZero Life Sciences — formerly GeneNews — earlier this year.

According to Oncore, BodyCheck will launch the test in the three countries during the first six months of the deal. BodyCheck has also agreed to sell a minimum of 275,000 tests, which will be processed by StageZero at its Virginia-based lab, translating to roughly $61.8 million in revenues to Oncore.

Additional terms were not disclosed.

"This is an important initial start for us in Europe," Oncore President and CEO Martin Verronneau said in a statement. "The signature of this first agreement less than four months after our partnership with StageZero Life Sciences is putting us ahead of schedule in creating sustainable value for our shareholders."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more